title: Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons.
abstract: Previously, we showed that type I interferon (alpha/beta interferon [IFN-alpha/beta]) can inhibit foot-and-mouth disease virus (FMDV) replication in cell culture, and swine inoculated with 10(9) PFU of human adenovirus type 5 expressing porcine IFN-alpha (Ad5-pIFN-alpha) were protected when challenged 1 day later. In this study, we found that type II pIFN (pIFN-gamma) also has antiviral activity against FMDV in cell culture and that, in combination with pIFN-alpha, it has a synergistic antiviral effect. We also observed that while each IFN alone induced a number of IFN-stimulated genes (ISGs), the combination resulted in a synergistic induction of some ISGs. To extend these studies to susceptible animals, we inoculated groups of swine with a control Ad5, 10(8) PFU of Ad5-pIFN-alpha, low- or high-dose Ad5-pIFN-gamma, or a combination of Ad5-pIFN-alpha and low- or high-dose Ad5-pIFN-gamma and challenged all groups with FMDV 1 day later. The control group and the groups inoculated with either Ad5-pIFN-alpha or a low dose of Ad5-pIFN-gamma developed clinical disease and viremia. However, the group that received the combination of both Ad5-IFNs with the low dose of Ad5-pIFN-gamma was completely protected from challenge and had no viremia. Similarly the groups inoculated with the combination of Ad5s with the higher dose of Ad5-pIFN-gamma or with only high-dose Ad5-pIFN-gamma were protected. The protected animals did not develop antibodies against viral nonstructural (NS) proteins, while all infected animals were NS protein seropositive. No antiviral activity or significant levels of IFNs were detected in the protected groups, but there was an induction of some ISGs. The results indicate that the combination of type I and II IFNs act synergistically to inhibit FMDV replication in vitro and in vivo.
authors: Plum Island Animal Disease Center, USDA, ARS, NAA, P.O. Box 848, Greenport, NY 11944, USA.
authors: Mauro Pires
authors: MP
authors: Moraes
authors: Teresa
authors: T
authors: de Los Santos
authors: Marla
authors: M
authors: Koster
authors: Traci
authors: T
authors: Turecek
authors: He
authors: H
authors: Wang
authors: Vladimir G
authors: VG
authors: Andreyev
authors: Marvin J
authors: MJ
authors: Grubman
mesh_terms: D000256:Adenoviridae; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D000998:Antiviral Agents / Q000276:immunology*; D002460:Cell Line; D006224:Cricetinae; D005536:Foot-and-Mouth Disease / Q000276:immunology / Q000517:prevention & control*; D029544:Foot-and-Mouth Disease Virus / Q000276:immunology*; D005786:Gene Expression Regulation / Q000276:immunology; D015316:Genetic Therapy; D006801:Humans; D016898:Interferon-alpha / Q000819:agonists / Q000235:genetics / Q000276:immunology*; D007371:Interferon-gamma / Q000819:agonists / Q000235:genetics / Q000276:immunology*; D012756:Sheep; D013552:Swine; D017361:Viral Nonstructural Proteins / Q000276:immunology; D014779:Virus Replication / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D000998:Antiviral Agents; D016898:Interferon-alpha; D017361:Viral Nonstructural Proteins; D007371:Interferon-gamma